Insulet to Participate in 44th Annual J.P. Morgan Healthcare Conference

About this update from Insulet Corporation

ACTON, Mass. --(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 11:15 a.m. (Pacific Time) . The live webcast and replay of the presentation will be accessible on the Insulet Investor Relations website: investors.insulet.com/events . About Insulet Corporation : Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts , is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit Insulet.com or omnipod.com . ©2025 Insulet Corporation . Omnipod is a registered trademark of Insulet Corporation . All rights reserved. View source version on businesswire.com : https://www.businesswire.com/news/home/20251216562336/en/ Investor Relations: Clare Trachtman Vice President, Investor Relations (978) 218-0889 [email protected] Media: Angela Geryak Wiczek Senior Director, Corporate Communications (978) 932-0611 [email protected] Source: Insulet Corporation

View stock analysis, news, and events for Insulet Corporation